

Tuberous Sclerosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/T9A6F6FFEA6BEN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T9A6F6FFEA6BEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Tuberous Sclerosis – Pipeline Insight, 2021," report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Tuberous Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Tuberous Sclerosis Understanding

Tuberous Sclerosis: Overview

Tuberous Sclerosis is a rare form of cancer affecting the peritoneum, the thin membrane surrounding your abdominal organs. The causes of Tuberous Sclerosis are unknown. Primary Tuberous Sclerosis is more common in women than in men. The symptoms of Tuberous Sclerosis resemble those of ovarian cancer. Many of these symptoms are due to buildup of fluid (ascites) in the abdomen. Tuberous Sclerosis symptoms may include: nausea, loss of appetite, vomiting, abnormal vaginal bleeding, rectum bleeding, feeling of fullness after breath and shortness of breath. Physical exam, Ultrasound, medical history are some procedures followed up for the diagnosis of Tuberous Sclerosis. The treatment usually depends upon the size, location and stage of cancer.

'Tuberous Sclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tuberous Sclerosis pipeline landscape is provided which includes the disease overview and Tuberous Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Tuberous Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tuberous Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tuberous Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Tuberous Sclerosis.

Tuberous Sclerosis Emerging Drugs Chapters

This segment of the Tuberous Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tuberous Sclerosis Emerging Drugs

GWP42003-P: GW Research Ltd

GWP42003-P also known as Epidiolex is an oral cannabidiol solution that GW Pharmaceuticals developed. Epidiolex is a plant-derived cannabidiol, a non-psychoactive marijuana extract. It is being studied in phase III stage for the treatment of patients with Tuberous sclerosis.

Ganaxolone: Marinus Pharmaceuticals

Ganaxolone is a GABAA receptor modulator that acts by regulating brain activity. GABA is the chief inhibitory neurotransmitter in the brain. Ganaxolone binds to one of the receptor subtypes, the GABAA receptor. When this receptor is activated, it increases the movement of chloride ions through a pore on the cell surface. This action changes the positive and negative charges inside and outside the cell, which inhibits the firing of the neuron. The drug is being evaluated in phase II stage for the treatment of Tuberous sclerosis.

Further product details are provided in the report.....

Tuberous Sclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Tuberous Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tuberous Sclerosis

There are approx. 7+ key companies which are developing the therapies for Tuberous Sclerosis. The companies which have their Tuberous Sclerosis drug candidates in the most advanced stage, i.e. phase III include, GW Research Ltd.

Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Tuberous Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tuberous Sclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tuberous Sclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tuberous Sclerosis drugs.

Tuberous Sclerosis Report Insights

Tuberous Sclerosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Tuberous Sclerosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Tuberous Sclerosis drugs?

How many Tuberous Sclerosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tuberous Sclerosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tuberous Sclerosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Tuberous Sclerosis and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- Tuberous Sclerosis: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Tuberous Sclerosis – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - Tuberous Sclerosis companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- Tuberous Sclerosis Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- GWP42003-P: GW Research Ltd
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Ganaxolone: Marinus Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Tuberous Sclerosis Key Companies

Tuberous Sclerosis Key Products

Tuberous Sclerosis- Unmet Needs

Tuberous Sclerosis- Market Drivers and Barriers

Tuberous Sclerosis- Future Perspectives and Conclusion

Tuberous Sclerosis Analyst Views

Tuberous Sclerosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Tuberous Sclerosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Tuberous Sclerosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Tuberos Sclerosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T9A6F6FFEA6BEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9A6F6FFEA6BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970